Core Insights - Moderna, Inc. is recognized as one of the top biotech stocks to invest in, with Brookline Capital Markets maintaining a Buy rating and a price target of $198 as of September 23 [1][3]. Company Overview - Moderna, Inc. is a biotechnology company focused on the discovery, development, and commercialization of mRNA-based medicines and vaccines, gaining significant recognition for its COVID-19 vaccine, one of the first mRNA vaccines delivered globally [4]. Vaccine Performance - The mNEXSPIKE/mRNA-1283 vaccine has shown a remarkable increase in neutralizing antibodies against the LP.8.1 variant, averaging over sixteen times compared to the initial COVID-19 vaccination results, which Brookline described as "remarkably strong" [2]. Sales Projections - Moderna's COVID-19 vaccine sales are projected to reach 10.9 million units in the U.S. this year, a decrease from the expected 14.6 million in 2024. Global sales are anticipated to be $2.1 billion in 2025 and could rise to $15.6 billion by 2030 [3].